drugset / Trial / NCT05913427

Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)

NCT05913427

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a prospective randomized, double blind, placebo controlled phase II study planned in patients with advanced ACC. The study will be conducted at ASST Spedali Civili Hospital and University of Brescia in Brescia.

Timeline

Start
2022-06-08
Primary completion
2027-06-08
Completion
2027-06-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Megestrol Acetate Other / unclassified 160 mg
Background Cisplatin Other / unclassified 40 mg/m2
Background Doxorubicin Other / unclassified 40 mg/m2
Background Etoposide Small molecule 100 mg/m2
Background Mitotane Small molecule